Mankind Pharma Limited reported earnings results for the third quarter and nine months ended December 31, 2025. For the third quarter, the company reported sales was INR 35,672 million compared to INR 31,987.9 million a year ago. Revenue was INR 36,399.5 million compared to INR 32,757.9 million a year ago. Net income was INR 4,087.5 million compared to INR 3,802.3 million a year ago. Basic earnings per share from continuing operations was INR 9.9 compared to INR 9.29 a year ago. Diluted earnings per share from continuing operations was INR 9.89 compared to INR 9.27 a year ago. Basic earnings per share was INR 9.9 compared to INR 9.45 a year ago. Diluted earnings per share was INR 9.89 compared to INR 9.44 a year ago.
For the nine months, sales was INR 108,347.1 million compared to INR 91,280.7 million a year ago. Revenue was INR 110,792.1 million compared to INR 94,135.3 million a year ago. Net income was INR 13,585.8 million compared to INR 15,701.9 million a year ago. Basic earnings per share from continuing operations was INR 32.91 compared to INR 38.87 a year ago. Diluted earnings per share from continuing operations was INR 32.87 compared to INR 38.79 a year ago. Basic earnings per share was INR 32.91 compared to INR 39.09 a year ago. Diluted earnings per share was INR 32.87 compared to INR 39.01 a year ago.
Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It also offers pet care, crop protection solutions, and veterinary care. It offers healthcare solutions for a range of healthcare needs with a portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/central nervous system, vitamins, minerals and nutrients, derma, fertility, and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, Rivotril, and others. Its subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Jaspack Industries Private Limited, and others.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
